INTRODUCTION
============

Necrotizing enterocolitis (NEC) characterized by intestinal ischemia and necrosis is one of the most common gastrointestinal emergencies in premature infants with very low birth weights (VLBWs), i.e., those who weigh less than 1,500 g ([@B1][@B2][@B3]). NEC affects about 5%--14% of VLBW neonates. Since NEC is a life-threatening gastrointestinal disease and an unpredictable surgical emergency, the overall mortality from NEC is high, ranging from 25% to 40% ([@B4][@B5]). Many researchers have tried to determine the precise pathophysiology of NEC by examining the various mechanisms that influence NEC development, such as the interaction between intraluminal microbiology and enteral nutrition and the change in inflammatory response by proinflammatory cytokines ([@B6][@B7][@B8][@B9][@B10][@B11]). Although several studies have been conducted and their associated hypotheses tested, substantial evidence to confirm risk factors (and effective therapies) for NEC has yet to be determined ([@B12][@B13]), other than prematurity and low birth weight ([@B14]).

Although several studies suggest that genetic factors affect NEC development in preterm infants with a potential susceptibility to NEC ([@B15][@B16]), the mechanisms underlying NEC are not fully understood. Previously, an NEC mice model has been used in many studies to establish the causes of or risk factors for human NEC due to several limitations in using human subjects, such as necrosis of human intestinal tissues and nonspecific inflammatory changes ([@B17]). However, although the animal models contribute to our understanding of disease mechanisms, limitations of reliability and reproducibility make the use of such models controversial ([@B18][@B19]).

Since transcripts are crucial intermediaries between the genome and the proteome, the detection of global gene expression is an important method for understanding molecular mechanisms of diseases and specific functions of particular tissues. Although microarray-based gene expression analysis has become the primary high-throughput platform in the past decade, this method has certain limitations, including high background noise and low resolution ([@B20]). Recently, RNA sequencing (RNA-Seq), using high-throughput next-generation sequencing methods, has become a powerful technology providing robust quantification of gene expression levels with a low background signal and high resolution ([@B21][@B22]).

MATERIALS AND METHODS
=====================

Study subjects
--------------

Study subjects were collected from Seoul National University Bundang Hospital, Gyemyoung University Dongsan Hospital, National Gyeongsang University Hospital, Donga University Hospital, and CHA University Bundang Hospital in Korea. The study protocol was approved by the institutional review board of the hospital, and written informed consent was provided by guardians of all patients. Premature infants at less than 32 weeks of gestational age and less than 1,500 g birth weight were enrolled in this study.

Two tissue sections (NEC lesion and adjacent normal regions) from the resected small bowel segment were collected as follows: 1) an NEC lesion that showed perforation or necrosis; and 2) adjacent normal tissue. Next, the tissues were immediately stored in liquid nitrogen until RNA extraction at −80°C; a portion of the tissues was evaluated by histological examination. Before RNA extraction, the mucosal layers of each tissue section were collected by the pediatric surgeon who performed the operation on the infants.

RNA isolation and quality control
---------------------------------

Total RNA was extracted from the dissected tissue sections (NEC lesion and adjacent normal regions) with the Nucleo-Spin-RNA-II-Kit (Macherey-Nagel, Düren, Germany) according to the manufacturer\'s protocol. RNA integrity and purity were analyzed with the Experion™ automated electrophoresis system (Bio-Rad, Hercules, CA, USA) with the Experion RNA StdSens chip. The mRNA was extracted and purified from the total RNA with the TruSeq stranded mRNA HT sample preparation kit (Illumina, Inc., San Diego, CA, USA), and this was followed by a purity check with Qubit 2.0 fluorometer (Life Technologies, Waltham, MA, USA) before proceeding to cDNA synthesis.

RNA-Seq and data analysis
-------------------------

RNA-Seq was carried out in order to identify differentially expressed genes in the NEC lesion and adjacent normal tissues. The isolated mRNA from 4 μg total RNA using oligo-dT magnetic beads was fragmented and primed at 94°C for 8 minutes, and then prepared for sequencing according to the protocol of the TruSeq stranded mRNA HT sample preparation kit (Illumina, Inc.). The resulting complementary DNA (cDNA) libraries were sequenced on the Illumina MiSeq system with 75 bp paired-end reads using the Illumina MiSeq sequencing kit v3 (150 cycles; Illumina, Inc.) following the manufacturer\'s instructions. Image processing and base calling were performed using the Illumina Real Time Analysis Software RTA v1.9.35. FastQ sequences were aligned to the human genome database (NCBI37/hg19) using TopHat v.2.0.12 with default parameters. The reads were mapped using the gene models as provided in the annotation GTF file (GRCh37.75). Gene expression values were determined using Cufflinks 2.2.1 release (<http://cole-trapnell-lab.github.io/cufflinks/>), and the FPKM (fragments per kilobase of exon per million fragments mapped) values were calculated for each transcript. Cufflinks default settings were adopted, and FPKM values were computed by summing the values of different transcripts of the same gene. To identify differentially expressed genes, a fold change over 1.5 between any pairwise comparisons was applied. For statistical analysis, data were examined by t-test.

Ethics statement
----------------

The present study protocol was reviewed and approved by the Institutional Review Board of Seoul National University Bundang Hospital (IRB No. B-1404-245-008). Informed consent was submitted by guardians of all patients.

RESULTS
=======

Patients
--------

A total of 5 NEC patients, with median gestational ages of 26 weeks and 2 days, birth weight of 922 g, and birth height of 34.2 cm, were enrolled in this study. None of the patients showed other congenital anomalies in the perinatal period, and the mothers had no antenatal/perinatal problems except for premature delivery. The exploratory laparotomy was performed in the NEC patients at a median gestational age of 29 weeks and 1 day. The operations included a segmental resection with temporary ileostomy or primary anastomosis. All patients recovered from NEC and survived without complications. Following surgery, a histological examination of NEC lesion and adjacent normal tissues from the patients was performed ([Fig. 1](#F1){ref-type="fig"}).

![NEC tissues for experiment and histological features. Arrows indicate 2 tissue sections (NEC lesion and adjacent normal regions) from the resected small bowel segment and each histological examination.\
NEC = necrotizing enterocolitis.](jkms-32-817-g001){#F1}

RNA-Seq analysis and gene expression comparison
-----------------------------------------------

To investigate the gene expression profiles for NEC development in preterm infants, RNA-Seq analysis using the Illumina MiSeq system was performed. Mapping of sequences resulted in an average read count of 11.75 × 10^6^ (± 4.36×10^6^) in 10 RNA samples composed of those from 2 paired small-bowel sections (NEC lesion and adjacent normal tissues) from each of 5 NEC patients. Of the 23,972 tested genes, a total of 65 genes (57 down-regulated and 8 up-regulated) were observed to have significantly different expression levels in the comparison between NEC lesion and adjacent normal tissues, based on a significance at fold change ≥ 1.5 and *P* ≤ 0.05 ([Table 1](#T1){ref-type="table"}). As a housekeeping gene, *GAPDH* was measured as 1,320.16 in NEC lesion and 1,255.20 in adjacent normal tissue (fold change = 1.05).

###### Down-/up-regulated genes in comparison of NEC lesion and adjacent normal tissues

![](jkms-32-817-i001)

  No.           Down-/up-regulation     Gene           Locus                       Expression level (FPKM, average)   Fold change (NEC lesion/adjacent normal)   *P* value   
  ------------- ----------------------- -------------- --------------------------- ---------------------------------- ------------------------------------------ ----------- ----------
  1             Down                    *HTR3A*        Chr11:113845796-113861034   0.71                               2.43                                       0.29        0.030
  2             Down                    *CPLX2*        Chr5:175223609-175311023    0.38                               1.09                                       0.35        0.040
  3             Down                    *PCP4*         Chr21:41239346-41301322     12.98                              36.34                                      0.36        0.050
  4             Down                    *PCSK2*        Chr20:17206751-17465222     0.39                               1.08                                       0.36        0.030
  5             Down                    *ST8SIA6*      Chr10:17362675-17496254     0.53                               1.39                                       0.38        0.050
  6             Down                    *SLC5A7*       Chr2:108602994-108630443    1.52                               3.98                                       0.38        0.050
  7             Down                    *PCDHGA6*      Chr5:140753650-140892546    0.44                               1.11                                       0.40        0.050
  8             Down                    *TMIE*         Chr3:46742822-46752413      0.45                               1.13                                       0.40        0.050
  9             Down                    *DNAJC6*       Chr1:65730376-65881552      1.69                               4.18                                       0.40        0.030
  10            Down                    *ELAVL4*       Chr1:50513685-50667540      5.64                               13.81                                      0.41        0.050
  11            Down                    *SULT4A1*      Chr22:44220386-44258378     2.24                               5.44                                       0.41        0.040
  12            Down                    *ATRNL1*       Chr10:116853123-117708496   0.59                               1.38                                       0.43        0.050
  13            Down                    *RET*          Chr10:43572516-43625797     3.38                               7.74                                       0.44        0.040
  14            Down                    *SPOCK2*       Chr10:73818791-73848790     4.04                               9.01                                       0.45        0.007
  15            Down                    *PTGES3L*      Chr17:41120104-41132545     1.65                               3.66                                       0.45        0.040
  16            Down                    *PTPRR*        Chr12:71031852-71314584     1.71                               3.76                                       0.45        0.030
  17            Down                    *CHODL*        Chr21:19289656-19639687     0.79                               1.73                                       0.46        0.010
  18            Down                    *NRXN3*        Chr14:78636715-80334633     2.96                               6.47                                       0.46        0.050
  19            Down                    *PIRT*         Chr17:10725791-10741418     0.73                               1.58                                       0.46        0.050
  20            Down                    *SCUBE1*       Chr22:43599228-43739394     0.57                               1.21                                       0.47        0.020
  21            Down                    *BZRAP1-AS1*   Chr17:56402810-56431088     1.07                               2.25                                       0.48        0.020
  22            Down                    *CAMK4*        Chr5:110559946-110820748    1.90                               3.99                                       0.48        \< 0.001
  23            Down                    *ACTG2*        Chr2:74120092-74146780      155.56                             322.23                                     0.48        0.050
  24            Down                    *FAM226B*      ChrX:72161567-72163589      0.54                               1.11                                       0.49        0.040
  25            Down                    *LOC151174*    Chr2:239133753-239140318    0.64                               1.31                                       0.49        0.050
  26            Down                    *MBNL1-AS1*    Chr3:151980404-151987415    2.53                               5.05                                       0.50        0.050
  27            Down                    *IQCH-AS1*     Chr15:67695948-67814182     1.46                               2.90                                       0.50        0.020
  28            Down                    *CDK5R1*       Chr17:30814104-30818271     1.13                               2.23                                       0.51        0.010
  29            Down                    *FOXN3-AS1*    Chr14:89883697-89886137     0.94                               1.85                                       0.51        0.030
  30            Down                    *DPF3*         Chr14:73136659-73360809     0.53                               1.04                                       0.51        \< 0.001
  31            Down                    *PTPRZ1*       Chr7:121513158-121702090    2.98                               5.70                                       0.52        0.020
  32            Down                    *SH3GL2*       Chr9:17578952-17797122      0.73                               1.37                                       0.53        0.050
  33            Down                    *SEPT6*        ChrX:118749687-118827333    14.02                              26.02                                      0.54        0.050
  34            Down                    *CTNND2*       Chr5:10971951-11904110      0.76                               1.41                                       0.54        0.020
  35            Down                    *BAI3*         Chr6:69345631-70099403      1.35                               2.48                                       0.54        0.040
  36            Down                    *RUNDC3A*      Chr17:42385926-42396038     4.46                               8.18                                       0.55        0.040
  37            Down                    *ARNT2*        Chr15:80696691-80890277     1.91                               3.42                                       0.56        0.030
  38            Down                    *SEMA4F*       Chr2:74881354-74910981      0.71                               1.26                                       0.56        0.020
  39            Down                    *FAM161B*      Chr14:74399694-74417117     1.15                               2.04                                       0.56        0.050
  40            Down                    *RPS6KL1*      Chr14:75370656-75389145     0.63                               1.11                                       0.57        0.020
  41            Down                    *GRIP1*        Chr12:66741210-67072925     0.89                               1.56                                       0.57        0.020
  42            Down                    *MACROD2*      Chr20:13976145-16033841     0.47                               0.82                                       0.57        0.010
  43            Down                    *VAMP1*        Chr12:6571403-6579843       3.88                               6.76                                       0.57        0.040
  44            Down                    *C3orf70*      Chr3:184795837-184870802    5.02                               8.49                                       0.59        0.040
  45            Down                    *RBM38*        Chr20:55966453-55984386     12.64                              20.81                                      0.61        0.020
  46            Down                    *TSPAN11*      Chr12:31079837-31149537     0.68                               1.11                                       0.61        0.020
  47            Down                    *LRRC4C*       Chr11:40135750-41481186     1.73                               2.81                                       0.62        0.030
  48            Down                    *BCL11A*       Chr2:60678301-60780633      2.83                               4.47                                       0.63        0.050
  49            Down                    *MANEAL*       Chr1:38259773-38267278      1.49                               2.33                                       0.64        0.050
  50            Down                    *MOXD1*        Chr6:132617193-132722664    5.43                               8.39                                       0.65        0.030
  51            Down                    *JAZF1*        Chr7:27870192-28220437      7.10                               10.87                                      0.65        0.050
  52            Down                    *TENM3*        Chr4:183245136-183724177    1.61                               2.43                                       0.66        0.010
  53            Down                    *PCDHB2*       Chr5:140474236-140476964    1.10                               1.65                                       0.67        0.050
  54            Down                    *PODXL2*       Chr3:127348001-127391653    4.85                               7.29                                       0.67        0.040
  55            Down                    *KLHL23*       Chr2:170590355-170608396    8.80                               13.15                                      0.67        0.050
  56            Down                    *GPC4*         ChrX:132435063-132549205    13.27                              19.31                                      0.69        0.030
  57            Down                    *PRKCE*        Chr2:45879042-46415129      3.62                               5.26                                       0.69        0.050
  58            Up                      *WT1*          Chr11:32409321-32457081     1.48                               0.39                                       3.82        0.050
  59            Up                      *SPAG4*        Chr20:34203808-34208965     1.65                               0.84                                       1.97        0.030
  60            Up                      *ADAMTS14*     Chr10:72432558-72522195     3.87                               2.05                                       1.89        0.040
  61            Up                      *GHRLOS*       Chr3:10322635-10335133      1.02                               0.55                                       1.85        0.030
  62            Up                      *DSTNP2*       Chr12:6993845-6994950       4.34                               2.35                                       1.85        0.020
  63            Up                      *ZNF503-AS2*   Chr10:77161285-77168740     1.07                               0.68                                       1.57        0.030
  64            Up                      *GBAP1*        Chr1:155183615-155197325    5.97                               3.91                                       1.53        0.030
  65            Up                      *MCOLN1*       Chr19:7587495-7598895       9.50                               6.22                                       1.53        0.020
  *GAPDH^\*^*   Chr12:6643584-6647537   1320.16        1255.20                     1.05                               \-                                                     

"-" in the fold change indicates down regulation.

NEC = necrotizing enterocolitis, Chr = chromosome.

^\*^*GAPDH* indicates a housekeeping gene.

Among the differentially expressed genes in NEC lesions compared to the adjacent normal region, *double PHD fingers 3* (*DPF3*, *P* \< 0.001) and *calcium/calmodulin-dependent protein kinase IV* (*CAMK4*, *P* \< 0.001) showed relatively robust association signals of upregulation, whereas downregulated genes showed weak signals ([Table 1](#T1){ref-type="table"}). In addition, 3 genes (*PCP4*, *PTPRR*, and *WT1*), which were recently reported as potential genes of NEC, were also observed to be differentially expressed in the NEC lesion ([Table 1](#T1){ref-type="table"}).

Ontology and pathway analyses of differentially expressed genes in NEC
----------------------------------------------------------------------

To assess the biological functions of the differentially expressed genes in NEC lesions and adjacent normal tissues, this study performed a gene ontology analysis using the WEB-based GEne SeT AnaLysis Toolkit (<http://bioinfo.vanderbilt.edu/webgestalt/>). As a result, 16 gene ontology categories (14 in biological processes and 2 in the cellular component) were predicted to affect NEC development in humans ([Table 2](#T2){ref-type="table"}), with the most significant signal at nervous system development (*P* = 9.3 × 10^-7^; *P~corr~* = 0.0003). In additional pathway analysis using Pathway Express (<http://vortex.cs.wayne.edu/projects.htm>) based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, genes involved in thyroid cancer and axon guidance showed significant associations ([Table 3](#T3){ref-type="table"}, *P~corr~* = 0.008 and 0.02, respectively).

###### Gene ontology analysis of differentially expressed genes in comparison of NEC lesion and adjacent normal tissues
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  Down-/up-regulation   Category             Gene ontology category                  Observed genes                                                                                                                                                                                                       Observed genes number   Expected genes number   Ratio of enrichment   Significance of enrichment   
  --------------------- -------------------- --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------- ----------------------- --------------------- ---------------------------- ----------
  Down                  Biological process   Nervous system development              *DPF3, LRRC4C, PCSK2, MACROD2, RET, PCP4, PCDHB2, CDK5R1, BCL11A, NRXN3, SEMA4F, SH3GL2, PTPRR, PTPRZ1, CPLX2, ARNT2, SPOCK2*                                                                                        17                      4.71                    3.61                  9.3 × 10^−7^                 \< 0.001
  Down                  Biological process   Neuron cell-cell adhesion               *CTNND2, CDK5R1, RET*                                                                                                                                                                                                3                       0.03                    91.44                 4.1 × 10^−6^                 0.001
  Down                  Biological process   System development                      *DPF3, LRRC4C, PCSK2, MACROD2, RET, CAMK4, PCP4, PCDHB2, CHODL, CDK5R1, RBM38, BCL11A, NRXN3, BAI3, SH3GL2, SEMA4F, SCUBE1, PTPRR, CPLX2, PTPRZ1, ARNT2, TMIE, SPOCK2*                                               23                      9.63                    2.39                  6.0 × 10^−6^                 0.002
  Down                  Biological process   Synaptic transmission                   *NRXN3, SH3GL2, VAMP1, HTR3A, CPLX2, CAMK4, GRIP1, SLC5A7, PCDHB2, CTNND2*                                                                                                                                           10                      1.78                    5.62                  7.2 × 10^−6^                 0.003
  Down                  Biological process   Single-multicellular organism process   *DPF3, LRRC4C, PCSK2, MACROD2, RET, CAMK4, SLC5A7, PCP4, PCDHB2, CHODL, ACTG2, CDK5R1, RBM38, BCL11A, NRXN3, BAI3, SH3GL2, VAMP1, SEMA4F, SCUBE1, PTPRR, HTR3A, CPLX2, PTPRZ1, GRIP1, ARNT2, TMIE, SPOCK2, CTNND2*   29                      15.34                   1.89                  1.2 × 10^−5^                 0.004
  Down                  Biological process   Multicellular organismal process        *DPF3, LRRC4C, PCSK2, MACROD2, RET, CAMK4, SLC5A7, PCP4, PCDHB2, CHODL, ACTG2, CDK5R1, RBM38, BCL11A, NRXN3, BAI3, SH3GL2, VAMP1, SEMA4F, SCUBE1, PTPRR, HTR3A, CPLX2, PTPRZ1, GRIP1, ARNT2, TMIE, SPOCK2, CTNND2*   29                      15.43                   1.88                  1.4 × 10^−5^                 0.005
  Down                  Biological process   Anatomical structure development        *DPF3, LRRC4C, PCSK2, MACROD2, RET, CAMK4, PCP4, PCDHB2, CHODL, CDK5R1, RBM38, BCL11A, NRXN3, BAI3, SH3GL2, SEMA4F, SCUBE1, PTPRR, CPLX2, PTPRZ1, ARNT2, TMIE, SPOCK2, CTNND2*                                       24                      11.02                   2.18                  1.7 × 10^−5^                 0.006
  Down                  Biological process   Multicellular organismal development    *DPF3, LRRC4C, PCSK2, MACROD2, RET, CAMK4, PCP4, PCDHB2, CHODL, CDK5R1, RBM38, BCL11A, NRXN3, BAI3, SH3GL2, SEMA4F, SCUBE1, PTPRR, CPLX2, PTPRZ1, ARNT2, TMIE, SPOCK2, CTNND2*                                       24                      11.15                   2.15                  2.1 × 10^−5^                 0.007
  Down                  Biological process   Transmission of nerve impulse           *NRXN3, SH3GL2, VAMP1, HTR3A, CPLX2, CAMK4, GRIP1, SLC5A7, PCDHB2, CTNND2*                                                                                                                                           10                      2.01                    4.98                  2.1 × 10^−5^                 0.007
  Down                  Biological process   Multicellular organismal signaling      *NRXN3, SH3GL2, VAMP1, HTR3A, CPLX2, CAMK4, GRIP1, SLC5A7, PCDHB2, CTNND2*                                                                                                                                           10                      2.05                    4.87                  2.5 × 10^−5^                 0.009
  Down                  Biological process   Neurotransmitter secretion              *NRXN3, SLC5A7, VAMP1, CPLX2*                                                                                                                                                                                        4                       0.27                    14.78                 \< 0.001                     0.030
  Down                  Biological process   Cell-cell signaling                     *NRXN3, SH3GL2, SEMA4F, VAMP1, HTR3A, CPLX2, CAMK4, GRIP1, SLC5A7, PCDHB2, CTNND2*                                                                                                                                   11                      3.00                    3.66                  \< 0.001                     0.030
  Down                  Cellular component   Synapse                                 *SEMA4F, VAMP1, SEPT6, HTR3A, CPLX2, GRIP1, CDK5R1, CTNND2*                                                                                                                                                          8                       1.20                    6.64                  2.2 × 10^−5^                 0.002
  Down                  Cellular component   Synapse part                            *GRIP1, SEMA4F, VAMP1, SEPT6, CTNND2, CDK5R1, HTR3A*                                                                                                                                                                 7                       0.91                    7.68                  3.0 × 10^−5^                 0.002
  Up                    Biological process   Extracellular structure organization    *ADAMTS14, WT1*                                                                                                                                                                                                      2                       0.06                    34.50                 0.001                        0.030
  Up                    Biological process   Extracellular matrix organization       *ADAMTS14, WT1*                                                                                                                                                                                                      2                       0.06                    34.67                 0.001                        0.030

Gene ontology categories with corrected *P* value of enrichment significance below 0.05 are shown.

NEC = necrotizing enterocolitis.

###### Potential pathways affected by differentially expressed genes in comparisons of NEC lesion and adjacent normal tissues
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  Pathway name     Differentially regulated genes   Input genes in pathway, %   Impact factor   Corrected *P* value
  ---------------- -------------------------------- --------------------------- --------------- ---------------------
  Thyroid cancer   *RET*                            1.587                       6.914           0.008
  Axon guidance    *LRRC4C, SEMA4F*                 3.175                       5.740           0.020

Corrected *P* value is obtained using the classical hypergeometric model ([@B32]).

NEC = necrotizing enterocolitis.

DISCUSSION
==========

Acquired conditions of diffuse necrotic injury to the intestinal segments are known to affect NEC development. Abnormal bacterial colonization and formula feeding have also been implicated as predisposing factors for NEC in humans ([@B23][@B24]). In addition, potential associations between NEC and environmental factors (such as microbiome, microbiome-intestinal reaction to breast milk or formula milk feeding, vaginal or cesarean section mode of delivery, and antibiotics) have been reported ([@B10][@B11][@B23][@B24][@B25]). Interestingly, a significant reduction of NEC in infants who were fed breast milk, compared to those who were fed formula, has been reported ([@B26]). Thus, many neonatologists have gone to great effort to manage the microbiome to prevent NEC development. Many neonatologists in Korea have changed their management protocols for preterm infants and observed a decreased incidence of NEC during the last few years.

NEC development may be multifactorial with the interplay between intrinsic and extrinsic factors. In addition, the main risk factor for NEC development in premature infants is thought to be intestinal immaturity ([@B23][@B27]), suggesting that intrinsic risk factors may be more important because premature infants have had a short exposure time to external environments. In this study, we hypothesized that global gene expression profiling may reveal distinct genetic differences between NEC lesion and adjacent normal region. Although candidate genes in this study did not reach great values of significance, several potential genes (such as *DPF3* and *CAMK4*) with relatively robust association signals were identified (*P* \< 0.001). These markers may have a role in NEC development. However, further replication and evaluation studies are needed.

As noted, this study showed relatively robust association signals at *DPF3* and *CAMK4*. *DPF3*, which is known as an epigenetic key factor for the development of heart and muscle tissue, has been reported to play a role in the neuronal differentiation process and also to take part in the disassembly of muscular fibers ([@B28]). In the different colon segments of Hirschsprung\'s disease, the gene product of *DPF3* has been observed to be lowly expressed in a stenotic segment, whereas it is highly expressed in proximal anastomosis ([@B29]), suggesting that *DPF3* may be dysregulated in colonic diseases such as NEC. In the case of *CAMK4*, although a direct association between *CAMK4* and NEC has not been reported, several connections in the literature related to necrosis can be found. In particular, *CAMK4* was observed to be involved in the necrosis factor (NF)-kappaB mediated signaling pathway in human endothelial cells ([@B30]). These previous results and our findings suggest that dysregulated expressions of genes identified in this study may contribute to NEC development.

Recently, the first RNA-Seq for gene expression profiling in NEC was reported ([@B31]). This first RNA-Seq study used ileum tissues from preterm patients with other diseases for the control, and several genes associated with immune functions (in particular, genes associated with Crohn\'s disease) were identified as contributing factors to NEC development, together with other candidate genes. When compared to our results, *PCP4* and *PTPRR* were overlapped; however, no connections in the literature related to NEC or related cellular functions (such as necrosis) could be found. Therefore, further studies are required to elucidate the association between these potential genes and NEC development.

So as to remove the heterogeneity of genetic background, this study excluded non-Korean parents. However, the study also has several limitations, such as insufficient sample size and lack of functional evaluation. The small sample size was due to the overall decreased incidence of NEC. In addition, normal tissues from the small bowel segment in infants without NEC or related diseases would have been ideal for the comparison analysis; however, it was limited to obtain these normal tissues. Although the first RNA-Seq analysis study of NEC used the ileum for the normal control ([@B31]), this study used adjacent normal tissues, and we do not rule out the possible effect of congenital diseases (such as small intestinal perforation, intestinal atresia, etc.).

In conclusion, despite study limitations, our preliminary results have identified potential involvements of certain genes (such as *DPF3* and *CAMK4*) in NEC development, suggesting that these genetic factors, perhaps together with epigenetic factors such as microbiomes and breast milk, may have a role in NEC development in humans. Further validation studies are needed to determine clinical applications of these potential targets.
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